Crinetics Pharmaceuticals (CRNX) Stock Price, News & Analysis

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Crinetics Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CRNX shares.
View CRNX analyst ratings or view top-rated stocks.

12 brokers have issued 1-year target prices for Crinetics Pharmaceuticals' shares. Their CRNX share price targets range from $35.00 to $80.00. On average, they anticipate the company's share price to reach $54.17 in the next twelve months. This suggests a possible upside of 25.2% from the stock's current price.
View analysts price targets for CRNX or view top-rated stocks among Wall Street analysts.

Crinetics Pharmaceuticals' stock was trading at $35.58 at the start of the year. Since then, CRNX stock has increased by 21.6% and is now trading at $43.25.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our CRNX earnings forecast.

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) issued its quarterly earnings data on Wednesday, February, 28th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by $0.01. Crinetics Pharmaceuticals had a negative net margin of 4,223.27% and a negative trailing twelve-month return on equity of 52.93%. Crinetics Pharmaceuticals's revenue for the quarter was down 100.0% compared to the same quarter last year. During the same quarter last year, the business posted ($0.84) earnings per share.

ETFs with the largest weight of Crinetics Pharmaceuticals (NASDAQ:CRNX) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), SPDR S&P Biotech ETF (XBI), First Trust Multi-Manager Small Cap Opportunities ETF (MMSC), Virtus LifeSci Biotech Clinical Trials ETF (BBC), BNY Mellon Innovators ETF (BKIV) and Direxion Daily S&P Biotech Bull 3x Shares (LABU).iShares Micro-Cap ETF (IWC).

6 employees have rated Crinetics Pharmaceuticals Chief Executive Officer R. Scott Struthers, Ph.D. on Glassdoor.com. R. Scott Struthers, Ph.D. has an approval rating of 100% among the company's employees. This puts R. Scott Struthers, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 68.0% of employees surveyed would recommend working at Crinetics Pharmaceuticals to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Crinetics Pharmaceuticals investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), G1 Therapeutics (GTHX), Kura Oncology (KURA), Otonomy (OTIC), Selecta Biosciences (SELB), TG Therapeutics (TGTX), Arbutus Biopharma (ABUS) and Applied Genetic Technologies (AGTC).

Crinetics Pharmaceuticals (CRNX) raised $80 million in an IPO on Wednesday, July 18th 2018. The company issued 5,000,000 shares at $15.00-$17.00 per share. J.P. Morgan, Leerink Partners and Piper Jaffray acted as the underwriters for the IPO.

Crinetics Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Hennion & Walsh Asset Management Inc. (0.05%). Insiders that own company stock include Ajay Madan, Alan Seth Krasner, Coelho Rogerio Vivaldi, Dana Pizzuti, Jeff E Knight, Marc Wilson, Matthew K Fust, Perceptive Advisors Llc, Richard Scott Struthers, Stephanie Okey and Stephen F Betz.
View institutional ownership trends.

Shares of CRNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.